

OPG (hBA-174): sc-4945

BACKGROUND

Bone morphogenesis and remodeling involve the formation of bone from osteoblasts and the resorption of bone by osteoclasts. The cytokine osteoprotegerin (OPG), also designated osteoclastogenesis inhibitory factor (OCIF), is known to inhibit osteoclast formation. A secreted glycoprotein, OPG is a member of the TNF receptor family that increases bone density and volume. OPG is thought to inhibit osteoclastogenesis by disrupting the cell-to-cell signaling between osteoblastic stromal cells and osteoclast progenitors. OPG is known to bind to TRAIL, a death domain-containing protein, and to inhibit TRAIL apoptosis in Jurkat cells. OPG also binds to osteoclast differentiation factor (ODF), also known as TRANCE/RANKL, a membrane-bound protein belonging to the TNF ligand family. Both TNF α and TNF β upregulate OPG expression, while the bone resorbing agent prostaglandin E2 downregulates OPG.

REFERENCES

1. Simonet, W.S., Lacey, D.L., Dunstan, C.R., Kelley, M., Chang, M.S., Luthy, R., Nguyen, H.Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H.L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T.M., Hill, D., Pattison, W., Campbell, P., Sander, S., Van, G., Tarpley, J., Derby, P., Lee, R., and Boyle, W.J. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Cell* 89 : 309-319.
2. Hill, P.A. 1998. Bone remodeling. *Br. J. Orthod.* 25: 101-107.
3. Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., Kanno, T., Murakami, A., Tsuda, E., Morinaga, T., and Higashio, K. 1998. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis *in vitro*. *Endocrinology* 139: 1329-1337.
4. Emery, J.G., McDonnell, P., Burke, M.B., Deen, K.C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E.R., Eichman, C., DiPrinzio, R., Dodds, R.A., James, I.E., Rosenberg, M., Lee, J.C., and Young, P.R. 1998. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. *J. Biol. Chem.* 273: 14363-14367.
5. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinoshita, M., Mochizuki, S.I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N., and Suda, T. 1998. Osteoclast differentiation is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *Proc. Natl. Acad. Sci. USA* 95: 3597-3602.
6. Brandstrom, H., Jonsson, K.B., Ohlsson, C., Vidal, O., Ljunghall, S., and Ljunggren, O. 1998. Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. *Biochem. Biophys. Res. Commun.* 247: 338-341.
7. Brandstrom, H., Jonsson, K.B., Vidal, O., Ljunghall, S., Ohlsson, C., and Ljunggren, O. 1998. Tumor necrosis factor alpha and beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. *Biochem. Biophys. Res. Commun.* 248: 454-457.

SOURCE

OPG (hBA-174) is produced in *E. coli* as 20 kDa biologically active protein corresponding to 174 amino acids of OPG of human origin.

PRODUCT

OPG (hBA-174) is purified from bacterial lysates (>98%); supplied as 50 μ g purified protein.

BIOLOGICAL ACTIVITY

OPG (hBA-174) is biologically active as determined by its ability to neutralize the stimulation of U-937 cells treated with 10 ng/ml of soluble RANKL (sRANKL).

RECONSTITUTION

In order to avoid freeze/thaw damaging of the active protein, dilute protein when first used to desired working concentration. Either a sterile filtered standard buffer (such as 50mM TRIS or 1X PBS) or water can be used for the dilution. Store any thawed aliquot in refrigeration at 2° C to 8° C for up to four weeks, and any frozen aliquot at -20° C to -80° C for up to one year. It is recommended that frozen aliquots be given an amount of standard cryopreservative (such as Ethylene Glycol or Glycerol 5-20% v/v), and refrigerated samples be given an amount of carrier protein (such as heat inactivated FBS or BSA to 0.1% v/v) or non-ionic detergent (such as Triton X-100 or Tween 20 to 0.005% v/v), to aid stability during storage.

STORAGE

Store desiccated at -20° C; stable for one year from the date of shipment.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.